Latin America Oral Anti-Diabetic Drug Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Latin America Oral Anti-Diabetic Drug Market is Segmented Into Drugs (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-d2 Receptor Agonists, Sodium-glucose Cotransport-2 (SGLT-2) Inhibitor, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Sulfonylureas, And Meglitinides), And Geography. The Report Offers the Value (in USD) and Volume (in Units) for the Above Segments.

Latin America Oral Anti-Diabetic Drug Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Latin America Oral Anti-Diabetic Drug Market Size

Latin America Oral Anti-Diabetic Drug Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
Market Size (2025) USD 3.36 Billion
Market Size (2030) USD 4.00 Billion
CAGR (2025 - 2030) 3.50 %

Major Players

Latin America Oral Anti-Diabetic Drug Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Latin America Oral Anti-Diabetic Drug Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Latin America Oral Anti-Diabetic Drug Market Analysis

The Latin America Oral Anti-Diabetic Drug Market size is estimated at USD 3.36 billion in 2025, and is expected to reach USD 4.00 billion by 2030, at a CAGR of 3.5% during the forecast period (2025-2030).

The ability to react to and adapt to populations, governments, and health systems around the world was put to the test by the COVID-19 pandemic. Brazil reported the first suspected and confirmed cases in Latin America on January 27 and February 26, respectively. The majority of Latin American nations failed to take prompt action to protect people with diabetes, which may have had a negative impact on people, health systems, and the economy. The ability to react to and adapt to populations, governments, and health systems around the world has been put to the test by the COVID-19 pandemic. 

Brazil presented the first suspected and first confirmed case in Latin America. The majority of Latin American nations failed to take prompt action to protect people with diabetes, which had a negative impact on people, health systems, and the economy.

Latin American nations have a high prevalence of diabetes, and Mexico is well known for having a sizable diabetic population as a result of the region's rising Type-2 diabetes prevalence. Over the past 40 years, the prevalence of Type-2 diabetes has increased, in large part due to the steadily rising obesity incidence and genetic vulnerability to the disease. Around 10% of the population currently has diabetes. About 90% of all diabetics worldwide will have Type-2 diabetes, which is the most common type in the Latin American region.

Depending on medications, the oral-drugs sector commands a substantial market share. Oral drugs are required by more than 100 million individuals in Latin America, including all of those with Type-1 diabetes and 10% to 25% of those with Type-2 diabetes. Due to the complexity of insulin production, there aren't many businesses on the market that produce it. Because of this, there is intense competition among these makers, who always work to satisfy the needs of the patient by supplying the highest-quality Oral-Anti Diabetes Drugs.

Latin America Oral Anti-Diabetic Drug Industry Overview

The Latin America oral anti-diabetes drug market is consolidated, with a few major manufacturers like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals having a global market presence. In contrast, the remaining manufacturers are confined to the other local or regional markets. Companies are focusing on innovations in diabetes drugs.

Latin America Oral Anti-Diabetic Drug Market Leaders

  1. Sanofi

  2. Astellas

  3. Astrazeneca

  4. Eli Lilly

  5. Janssen Pharmaceuticals

  6. *Disclaimer: Major Players sorted in no particular order
Latin America Oral Anti-Diabetic Drug Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Latin America Oral Anti-Diabetic Drug Market News

  • Septmber 2023: FDA approves another SGLT2 Inhibitor for Treating cardivosular. Empagliflozin adds indication in adults, regardless of diabetes status.
  • March 2022: Oramed announced ORMD-0801 (a new molecule) is being evaluated in two pivotal Phase 3 trials and can be the first oral insulin capsule that has the most convenient and safest way to deliver insulin therapy. This drug is expected to be a game-changer in the insulin and oral anti-diabetes drugs markets. Oramed is also developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).

Latin America Oral Anti-Diabetic Drug Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Oral Anti-diabetic drugs
    • 5.1.1 Biguanides
    • 5.1.2 Alpha-Glucosidase Inhibitors
    • 5.1.3 Dopamine D2 Receptor Agonist
    • 5.1.4 SGLT-2 inhibitors
    • 5.1.4.1 Invokana (Canagliflozin)
    • 5.1.4.2 Jardiance (Empagliflozin)
    • 5.1.4.3 Farxiga/Forxiga (Dapagliflozin)
    • 5.1.4.4 Suglat (Ipragliflozin)
    • 5.1.5 DPP-4 inhibitors
    • 5.1.5.1 Onglyza (Saxagliptin)
    • 5.1.5.2 Tradjenta (Linagliptin)
    • 5.1.5.3 Vipidia/Nesina(Alogliptin)
    • 5.1.5.4 Galvus (Vildagliptin)
    • 5.1.6 Sulfonylureas
    • 5.1.7 Meglitinides
  • 5.2 Geography
    • 5.2.1 Brazil
    • 5.2.2 Mexico
    • 5.2.3 Rest of Latin America

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetic Population
  • 6.2 Type-2 Diabetic Population

7. COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Takeda
    • 7.1.2 Novo Nordisk
    • 7.1.3 Pfizer
    • 7.1.4 Eli Lilly
    • 7.1.5 Janssen Pharmaceuticals
    • 7.1.6 Astellas
    • 7.1.7 Boehringer Ingelheim
    • 7.1.8 Merck And Co.
    • 7.1.9 AstraZeneca
    • 7.1.10 Bristol Myers Squibb
    • 7.1.11 Novartis
    • 7.1.12 Sanofi
  • *List Not Exhaustive

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments .
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Latin America Oral Anti-Diabetic Drug Industry Segmentation

Antihyperglycemic medications are taken orally to lower blood glucose levels. They are frequently employed in the management of type 2 diabetes. The Latin America Oral Anti-Diabetic Drug Market is segmented into drugs, and Geography. The report offers the value (in USD) and volume (in Units) for the above segments.

Oral Anti-diabetic drugs Biguanides
Alpha-Glucosidase Inhibitors
Dopamine D2 Receptor Agonist
SGLT-2 inhibitors Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP-4 inhibitors Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Meglitinides
Geography Brazil
Mexico
Rest of Latin America
Need A Different Region or Segment?
Customize Now

Latin America Oral Anti-Diabetic Drug Market Research FAQs

How big is the Latin America Oral Anti-Diabetic Drug Market?

The Latin America Oral Anti-Diabetic Drug Market size is expected to reach USD 3.36 billion in 2025 and grow at a CAGR of 3.5% to reach USD 4.00 billion by 2030.

What is the current Latin America Oral Anti-Diabetic Drug Market size?

In 2025, the Latin America Oral Anti-Diabetic Drug Market size is expected to reach USD 3.36 billion.

Who are the key players in Latin America Oral Anti-Diabetic Drug Market?

Sanofi, Astellas, Astrazeneca, Eli Lilly and Janssen Pharmaceuticals are the major companies operating in the Latin America Oral Anti-Diabetic Drug Market.

What years does this Latin America Oral Anti-Diabetic Drug Market cover, and what was the market size in 2024?

In 2024, the Latin America Oral Anti-Diabetic Drug Market size was estimated at USD 3.24 billion. The report covers the Latin America Oral Anti-Diabetic Drug Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Latin America Oral Anti-Diabetic Drug Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Latin America Oral Anti-Diabetic Drug Industry Report

Statistics for the 2025 Latin America Oral Anti-Diabetic Drug market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Latin America Oral Anti-Diabetic Drug analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.